Literature DB >> 32651540

Genome instability in multiple myeloma.

Carl Jannes Neuse1,2, Oliver C Lomas1, Christoph Schliemann2, Yu Jia Shen1, Salomon Manier3, Mark Bustoros4,5, Irene M Ghobrial6,7.   

Abstract

Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by clonal proliferation of plasma cells and a heterogenous genomic landscape. Copy number and structural changes due to chromosomal instability (CIN) are common features of MM. In this review, we describe how primary and secondary genetic events caused by CIN can contribute to increased instability across the genome of malignant plasma cells; with a focus on specific driver genomic events, and how they interfere with cell-cycle checkpoints, to prompt accelerated proliferation. We also provide insight into other forms of CIN, such as chromothripsis and chromoplexy. We evaluate how the tumor microenvironment can contribute to a further increase in chromosomal instability in myeloma cells. Lastly, we highlight the role of certain mutational signatures in leading to high mutation rate and genome instability in certain MM patients. We suggest that assessing CIN in MM and its precursors states may help improve predicting the risk of progression to symptomatic disease and relapse and identifying future therapeutic targets.

Entities:  

Year:  2020        PMID: 32651540     DOI: 10.1038/s41375-020-0921-y

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  23 in total

1.  YTHDF2 promotes multiple myeloma cell proliferation via STAT5A/MAP2K2/p-ERK axis.

Authors:  Zhen Hua; Rongfang Wei; Mengjie Guo; Zigen Lin; Xichao Yu; Xinying Li; Chunyan Gu; Ye Yang
Journal:  Oncogene       Date:  2022-01-24       Impact factor: 8.756

Review 2.  The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).

Authors:  F Nguyen-Khac; A Bidet; A Daudignon; M Lafage-Pochitaloff; G Ameye; C Bilhou-Nabéra; E Chapiro; M A Collonge-Rame; W Cuccuini; N Douet-Guilbert; V Eclache; I Luquet; L Michaux; N Nadal; D Penther; B Quilichini; C Terre; C Lefebvre; M-B Troadec; L Véronèse
Journal:  Leukemia       Date:  2022-04-16       Impact factor: 12.883

Review 3.  Genomic Instability in Multiple Myeloma: A "Non-Coding RNA" Perspective.

Authors:  Elisa Taiana; Maria Eugenia Gallo Cantafio; Vanessa Katia Favasuli; Cecilia Bandini; Giuseppe Viglietto; Roberto Piva; Antonino Neri; Nicola Amodio
Journal:  Cancers (Basel)       Date:  2021-04-28       Impact factor: 6.639

4.  Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma.

Authors:  Bachisio Ziccheddu; Matteo C Da Vià; Francesco Maura; Niccolò Bolli; Marta Lionetti; Akihiro Maeda; Silvia Morlupi; Matteo Dugo; Katia Todoerti; Stefania Oliva; Mattia D'Agostino; Paolo Corradini; Ola Landgren; Francesco Iorio; Loredana Pettine; Alessandra Pompa; Martina Manzoni; Luca Baldini; Antonino Neri
Journal:  Clin Cancer Res       Date:  2021-09-15       Impact factor: 12.531

5.  Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.

Authors:  Mehmet Kemal Samur; Mariateresa Fulciniti; Anil Aktas Samur; Abdul Hamid Bazarbachi; Yu-Tzu Tai; Rao Prabhala; Alejandro Alonso; Adam S Sperling; Timothy Campbell; Fabio Petrocca; Kristen Hege; Shari Kaiser; Hervé Avet Loiseau; Kenneth C Anderson; Nikhil C Munshi
Journal:  Nat Commun       Date:  2021-02-08       Impact factor: 14.919

Review 6.  Novel Experimental Drugs for Treatment of Multiple Myeloma.

Authors:  Massimo Offidani; Laura Corvatta; Sonia Morè; Attilio Olivieri
Journal:  J Exp Pharmacol       Date:  2021-03-09

7.  Pulmonary Lymphangitic Spread of Multiple Myeloma as Early Relapse after Autologous Stem Cell Transplantation.

Authors:  Bicky Thapa; Gulrayz Ahmed; Meera Mohan; Volodymyr Shponka; Parameswaran Hari
Journal:  Case Rep Hematol       Date:  2021-04-03

Review 8.  Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications.

Authors:  Linchun Xu; Yongzhong Su
Journal:  Exp Hematol Oncol       Date:  2021-07-20

9.  Identification of patients at high risk of secondary extramedullary multiple myeloma development.

Authors:  Martin Stork; Sabina Sevcikova; Jiri Minarik; Petra Krhovska; Jakub Radocha; Lenka Pospisilova; Lucie Brozova; Jiri Jarkovsky; Ivan Spicka; Jan Straub; Petr Pavlicek; Alexandra Jungova; Tomas Jelinek; Viera Sandecka; Vladimir Maisnar; Roman Hajek; Ludek Pour
Journal:  Br J Haematol       Date:  2021-11-02       Impact factor: 8.615

Review 10.  Multiple Myeloma: Heterogeneous in Every Way.

Authors:  Anaïs Schavgoulidze; Titouan Cazaubiel; Aurore Perrot; Hervé Avet-Loiseau; Jill Corre
Journal:  Cancers (Basel)       Date:  2021-03-13       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.